The p16 expression assay is currently used clinically to identify HPV infection in HNSCC patients, because HPV+ individuals have very different prognosis and treatment options from those with non‐virus‐associated HNSCC. Here, CDKN2A is linked to head and neck squamous cell carcinoma.